Latest Tanabe Pharma News & Updates

See the latest news and media coverage for Tanabe Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tanabe Pharma

Pharmaceutical company specializing in prescription medicines

tanabe-pharma.com

Headquarters: Osaka, Japan
Founded year: 1678
Company type: Public company
Number of employees: 5,000–10,000
Industry: Pharmaceuticals

Last updated Yesterday

Latest news about Tanabe Pharma

In short: Tanabe Pharma, now Bain-owned, divested RADICAVA to Shionogi and dersimelagon to LEO Pharma, advancing its pipeline.

Company announcements

October 29 Tanabe Pharma

Tanabe Pharma Files for Approval in Japan with Nippon Shinyaku License

The company filed for approval of loncastuximab tesirine and signed an exclusive sublicense agreement with Nippon Shinyaku for commercialization rights.

September 28 Tanabe Pharma

Tanabe Pharma out-licenses MT-2990 to Tolerance Bio

Tanabe Pharma secured up to USD560 million in potential payments and retains Japanese rights for the antibody drug.

September 18 Tanabe Pharma

Tanabe Pharma announces FDA acceptance of NDA for dersimelagon

The application receives Priority Review with a decision expected by February 2027. Rights were transferred to LEO Pharma while Tanabe handles US approval.

September 16 Tanabe Pharma

Tanabe Pharma receives approval in Japan for additional indication of generalized Myasthenia Gravis

The company obtained regulatory approval on September 16, 2026, for UPLIZNA® to treat this condition.

Media coverage

Yesterday MarketScreener

Mineralys Therapeutics, Inc. Terminates License Agreement with Tanabe Pharma Corporation and Assigns Intellectual Property Rights

Mineralys Therapeutics, Inc. announced that it and Tanabe Pharma Corporation were previously parties to that certain License Agreement, dated July 9, 2020 and amended on...

October 28 MarketScreener

Nippon Shinyaku : Enters into Exclusive Sublicense Agreement with Tanabe Pharma to Commercialize loncastuximab tesirine-lpyl (MT-2111) for Relapsed or Refractory Diffuse Large ...

Kyoto, Japan, October 29, 2026 - Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) today announced that it entered into an exclusive...

October 22 note

Bain Capital x Mitsubishi Tanabe Pharma | Why the chemical parent company sold off its ...

On February 7, 2025, Mitsubishi Chemical Group announced that it would transfer its wholly-owned subsidiary, Mitsubishi Tanabe Pharma, to Bain Capital for approximately 510 billion...

September 28 JIJI PRESS

Tolerance Bio Licenses Clinical-Stage Anti-IL-33 Monoclonal Antibody from Tanabe Pharma to ...

Company planning Phase 2 clinical development beginning in 2027 as it builds a pipeline of complementary modalities to improve thymic function for better healthspan PHILADELPHIA...

Never miss news about Tanabe Pharma

Track Tanabe Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Tanabe Pharma competitors & trending companies

Browse news for competitors to Tanabe Pharma and other trending companies.